Previous 10 | Next 10 |
Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia PR Newswire Oral presentation highlighted Iomab-B improves overall survival in patients with TP53 mutation with ac...
Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Acti...
2023-11-03 18:08:52 ET Summary Actinium Pharmaceuticals continues to make progress with their radiolabelled CD45 antibody Iomab-B, which has potential beyond market expectations. The main pipeline update is the presentation of findings in patients with TP53 mutation, showing impro...
Actinium Pharmaceuticals to Attend Bio-Europe Munich 2023 PR Newswire NEW YORK , Nov. 2, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announc...
Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median Overall Survival in Relapsed or Refractory AML Patients with Highly Unfavorable TP53 Gene Mutation in the Phase 3 SIERRA Trial PR Newswire - ...
Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell Therapy PR Newswire - Ongoing clinical trial is the first ever to combine targeted radiotherapy conditi...
Actinium Pharma Highlights Abstract Accepted for Poster Presentation at the SITC 38th Annual Meeting PR Newswire NEW YORK , Sept. 27, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the develop...
2023-09-15 19:02:20 ET Summary Actinium is making radiolabeled antibodies for use in hematologic cancers. Previously reported phase 3 trial results give a strong indicator of success at the regulatory level. No respect from the market means Actinium could be in a good position...
2023-09-10 15:17:31 ET HSBC initiated coverage of 11 US biopharma stocks this week, adding IQVIA, Zoetis, bluebird and Actinium Pharmaceuticals to its “buy” ratings list. IQVIA ( NYSE: IQV ) and Zoetis ( NYSE: ZTS ) were labeled “quality growthȁ...
Actinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHO PR Newswire - Extended follow-up in the Actimab-A + CLAG-M trial showed median overall sur...
News, Short Squeeze, Breakout and More Instantly...
Actinium Pharmaceuticals Inc. Company Name:
ATNM Stock Symbol:
NYSE Market:
2024-05-16 06:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity PR Newswire - KOL and principal investigator, Dr. Farrukh Awan , Professor of Medicine, Division of Hematology Oncology at Univer...
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA Trial PR Newswire ...